tbuckley/cabot-search huggingface dataset:
<i>SLC2A12</i>of SLC2 Gene Family in Bird Provides Functional Compensation for the Loss of<i>SLC2A4</i>Gene in Other Vertebrates
Authors: Ying Xiong, Fumin Lei
Journal: Molecular Biology and Evolution (2020)

Avian genomes are small and lack some genes that are conserved in the genomes of most other vertebrates including nonavian sauropsids. One hypothesis stated that paralogs may provide biochemical or physiological compensation for certain gene losses; however, no functional evidence has been reported to date. By integrating evolutionary analysis, physiological genomics, and experimental gene interference, we clearly demonstrate functional compensation for gene loss. A large-scale phylogenetic analysis of over 1,400 SLC2 gene sequences identifies six new SLC2 genes from nonmammalian vertebrates and divides the SLC2 gene family into four classes. Vertebrates retain class III SLC2 genes but partially lack the more recent duplicates of classes I and II. Birds appear to have completely lost the SLC2A4 gene that encodes an important insulin-sensitive GLUT in mammals. We found strong evidence for positive selection, indicating that the N-termini of SLC2A4 and SLC2A12 have undergone diversifying selection in birds and mammals, and there is a significant correlation between SLC2A12 functionality and basal metabolic rates in endotherms. Physiological genomics have uncovered that SLC2A12 expression and allelic variants are associated with insulin sensitivity and blood glucose levels in wild birds. Functional tests have indicated that SLC2A12 abrogation causes hyperglycemia, insulin resistance, and high relative activity, thus increasing energy expenditures that resemble a diabetic phenotype. These analyses suggest that the SLC2A12 gene not only functionally compensates insulin response for SLC2A4 loss but also affects daily physical behavior and basal metabolic rate during bird evolution, highlighting that older genes retain a higher level of functional diversification.
원저 / 군입영 대상자의 HBsAg 양성률과 anti-HCV 항체 양성률의 변화
Authors: 안병민(Byung Min An), 정규원(Gyu Won Jung), 김록권(Rok Gwon Kim), 이동수(Dong Soo Lee), 이강문(Kang Moon Lee), 박영민(Young Min Park), 이영석(Young Suk Lee), 이원철(Won Chul Lee), 맹광호(Gwang Ho Maeng)
Journal: Clinical and Molecular Hepatology (2000)

Background/Aims: Before the introduction of the HBV vaccination programs, the positivity of HBsAg among the general population was reported to be around 8% in Korea. Although recent reports revealed somewhat decreased values, a wide range of variation exists according to the authors. Major movements to control HBV infection include the programs such as the introduction of HBV vaccination in 1983, mass inoculation of the elementary school children since 1988 and inclusion of type B hepatitis in 1995 in Class III legal epidemics. The purpose of the present study was to examine the changing trend of the positivities of HBsAg, HBeAg and anti-HCV in army draftees in Korea since we believed that they are an ideal study group with a set of fixed variables such as gender and age. Methods: From January 1, 1993 to December 31, 1999, we evaluated a total of 498,206 male army draftees for serum ALT, HBsAg, HBeAg and anti-HCV antibody. HBsAg (Genedia, Yongin, Korea) and HBeAg (Amrad, Austrailia) were examined by EIA and Immunochromatography, respectively. Anti-HCV antibody was tested by 3rd generation EIA (Genedia, Yongin, Korea). Serum ALT was determined by autoanalyser, Polystat 2000 (Hitachi, Japan). Results: The majority of the draftees were 20 years old (68.8%). The positivity of HBsAg gradually decreased from 5.8% in 1993 to 4.3% in 1999(mean 4.8%). The positivity of HBeAg among the asymptomatic HBsAg carriers ranged from 47.9% to 55.6%(mean 51.8%). The positivity of anti-HCV antibody was seen in the range from 0.09% to 0.29%(mean 0.18%), and 84.5% showed normal ALT. The positivity of HBsAg among the anti-HCV positive subjects was 6.6%. Conclusion: The HBsAg positivity has significantly(p=0.001) decreased for the past 7 years. However, the positivity of anti-HCV antibody showed no significant pattern of change during the same period.
Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup
Authors: Takahisa Matsuda, Takahiro Fujii, Yasushi Sano, Shin-ei Kudo, Yasushi Oda, Kinichi Hotta, Tadakazu Shimoda, Yutaka Saito, Nozomu Kobayashi, Masau Sekiguchi, Kazuo Konishi, Hiroaki Ikematsu, Hiroyasu Iishi, Yoji Takeuchi, Masahiro Igarashi, Kiyonori Kobayashi, Miwa Sada, Yuichiro Yamaguchi, Kiwamu Hasuda, Tomoaki Shinohara, Hideki Ishikawa, Yoshitaka Murakami, Hirokazu Taniguchi, Takahiro Fujimori, Yoichi Ajioka, Shigeaki Yoshida
Journal: Gut (2020)

To assess whether follow-up colonoscopy after polypectomy at 3 years only, or at 1 and 3 years would effectively detect advanced neoplasia (AN), including nonpolypoid colorectal neoplasms (NP-CRNs).
Mechanisms of Leukemia Stem Cell Plasticity Revealed By Single Cell Analysis
Authors: R. Grant Rowe, George Q. Daley, Trista E. North, William Marion, Yana Pikman, Marian H. Harris, Vivian Morris, Edroaldo Lummertz da rocha, Alex K. Shalek, Travis Hughes, Prerana Sensharma, Dahai Wang, Patricia Sousa, Shannan Ho Sui, Sergey Naumenko, Renan Vinicius Da Silva
Journal: Blood (2020)
A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children
Authors: Thakur Satbir, Son Tran, Mohit Jain, Austin Lewis, Luis Murguia-Favela, Faisal M Khan, Kevin J. Bielamowicz, Olena Vaske, Victor A. Lewis, Norman J. Lacayo, Aru Narendran
Journal: Blood (2020)
Enhanced expression of angiotensin‐converting enzyme 2 in psoriatic skin and its upregulation in keratinocytes by interferon‐γ: implication of inflammatory milieu in skin tropism of SARS‐CoV‐2
Authors: M.K. Tembhre, A.S. Parihar, V.K. Sharma, S. Imran, N. Bhari, R. Lakshmy, A. Bhalla
Journal: British Journal of Dermatology (2020)

The novel coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a challenging situation globally due to its contagion nature. SARS-CoV-2 enters the host cell by interacting with the ACE2 (angiotensin converting enzyme 2) receptor present on cell surface through its receptor-binding domain (RBD) of spike protein (1). Host proteases mainly TMPRSS2 plays a vital role in cleaving the SARS-CoV-2 spike protein thereby enabling the virus to enter host cell via endocytosis. SARS-CoV-2 mainly affects the respiratory system of the infected host, however, its manifestation to other organs have also been reported (2).
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)
Authors: Jodi J Lipof, Dharmini Manogna, Andrea M. Baran, Bassil Said, Michael W. Becker, Jason H. Mendler, Omar S. Aljitawi, Kristen Marie O'Dwyer, Eric Huselton, Richard Burack, Margaret Blaney, Taylor Douglas, Jane L. Liesveld, Kah Poh Loh
Journal: Blood (2020)
Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients
Authors: Sebastià Franch-Expósito, Preethi Srinivasan, Ryan Ptashkin, Chaitanya Bandlamudi, Kelly L. Bolton, Erika Gedvilaite, Kamal Menghrajani, Diana Mandelker, Elizabeth Comen, Larry Norton, Ryma Benayed, Teng Gao, Elli Papaemmanuil, Barry S Taylor, Ross L. Levine, Michael F. Berger, Ahmet Zehir
Journal: Blood (2020)
Dynamic Change of Peripheral Blood WT1-mRNA within Three Cycles of Azacitidine Therapy Predicts Treatment Response in High-Risk Myelodysplastic Syndrome
Authors: Shinpei Harada, Masahiro Onozawa, Daisuke Hidaka, Shota Yokoyama, Hajime Senjo, Shogo Takahashi, Reiki Ogasawara, Akio Mori, Shuichi Ota, Takeshi Kondo, Takanori Teshima
Journal: Blood (2020)
Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia
Authors: Benjamin J. Huang, Jenny L. Smith, Rhonda E. Ries, Amanda R. Leonti, Erin Lynn Crowgey, Scott N. Furlan, Timothy Shaw, Lisa Wei, Yi-Cheng Wang, Robert B. Gerbing, Todd A. Alonzo, Todd M. Cooper, Edward A. Kolb, Xiaotu Ma, Jason E. Farrar, Timothy Junius Triche, Soheil Meshinchi
Journal: Blood (2020)
SP0097 Macromolecules with roles in cartilage and bone homeostasis
Authors: D Heinegård
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> The extracellular matrix of skeletal tissues contains molecules with key roles in tissue homeostasis. Particularly important are those that are part of the collagen network and maintains its integrity. Examples are members of the thrombospondin family, in cartilage particularly COMP, and members of the family of extracellular leucine rich repeat (LRR) proteins. These proteins have key roles in the assembly of the collagen II fibrillar network and have the capacity to crosslink neighbouring fibrils by containing at least two functional domains, one binding to one fibril and the other binding to another fibril. An example is decorin showing an interaction site of the core proteins on one hand, while another being the dermatan sulfate side chain. Similarly fibromodulin contains structures with potential for interactions with different collagen fibrillar structures. Current data indicate that an early event in osteoarthritis is the fragmentation of the binding proteins to separate the functional domains. This will result in an inability of the collagen network to prevent swelling of the tissue and maintain functionality. The alterations elicit a response where molecules that have roles in catalysing collagen fibril assembly are produced. Such regulating proteins include COMP. This modular protein contains five identical subunits held together close to their C-terminus and having a C-terminal end globular domain that promotes tight binding to collagen. COMP appears to bring together the collagen monomers and catalyse the formation of early fibrils in a chaperon like mode. It is also present, apparently crosslinking completed fibrils by simultaneously binding several collagen IX molecules that are covalently bound on the surface of the collagen II/XI fibres. Other matrix constituents like PRELP and chondroadherin bind to cell surface molecules, apparently involved in signalling to the cells. These two molecules also bind to collagens I and II. Cell binding proteins have key roles in bone turnover. Examples are osteopontin, a protein binding the αvβ3 as well as the α4β1 integrin. The protein is produced by the osteoblast and binds to the bone mineralized surface. It then appears to have a central role in recruiting and promoting the development of osteoclast precursors to a fully functional cell. Osteopontin is also expressed by a number of cells in the inflammatory system. It is likely that release of osteopontin in joint destruction will influence the inflammatory response. Other bone proteins with a capacity to bind αvβ3 include BSP and osteoadherin. Their role in bone turnover and interactions with other tissues remains to be elucidated, but available data indicate primary functions in bone formation.
Malaria is a cause of iron deficiency in African children
Authors: John Muthii Muriuki, Alexander J. Mentzer, Ruth Mitchell, Emily L. Webb, Anthony O. Etyang, Catherine Kyobutungi, Alireza Morovat, Wandia Kimita, Francis M. Ndungu, Alex W. Macharia, Caroline J. Ngetsa, Johnstone Makale, Swaib A. Lule, Solomon K. Musani, Laura M. Raffield, Clare L. Cutland, Sodiomon B. Sirima, Amidou Diarra, Alfred B. Tiono, Michal Fried, Moses Gwamaka, Seth Adu-Afarwuah, James P. Wirth, Rita Wegmüller, Shabir A. Madhi, Robert W. Snow, Adrian V. S. Hill, Kirk A. Rockett, Manjinder S. Sandhu, Dominic P. Kwiatkowski, Andrew M. Prentice, Kendra A. Byrd, Alex Ndjebayi, Christine P. Stewart, Reina Engle-Stone, Tim J. Green, Crystal D. Karakochuk, Parminder S. Suchdev, Philip Bejon, Patrick E. Duffy, George Davey Smith, Alison M. Elliott, Thomas N. Williams, Sarah H. Atkinson
Journal: Nature Medicine (2021)
Adjunction of a Fish Oil Emulsion to Cytarabine and Daunorubicin Induction Chemotherapy in High-Risk AML. the Famyly Pilot Study from the French Innovative Leukemia Organization (FILO)
Authors: Emmanuel Gyan, Arnaud Pigneux, Mathilde Hunault-Berger, Pierre Peterlin, Martin Carre, Jacques-Olivier Bay, Caroline Bonmati, Maria Pilar Gallego Hernanz, Bruno Lioure, Philippe Bertrand, Nicolas Vallet, David Ternant, François Darrouzain, Frederic Picou, Marie C Bene, Christian Recher, Olivier Herault
Journal: Blood (2020)
Hematology Utilization Group Studies Part VII (HUGS VII): Costs and Impact of Disease in Older Persons with Hemophilia
Authors: Randall Curtis, Marilyn J Manco-Johnson, Barbara A. Konkle, Roshni Kulkarni, Joanne Wu, Judith Baker, Megan M. Ullman, Duc Quang Tran, Michael B. Nichol
Journal: Blood (2020)
Fusion Gene Map of Acute Myeloid Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 400 Cases in a Single Center
Authors: Xue Chen, Fang Wang, Panxiang Cao, Xiaoli Ma, Lili Yuan, Yang Zhang, Daijing Nie, Jiaqi Chen, Xiaosu Zhou, Ming Liu, Zhixiu Liu, Mingyue Liu, Hongxing Liu
Journal: Blood (2020)
Clostridium Difficile Infection Is Independently Associated with Significantly Worse Outcomes in Acute Leukemia Patients Undergoing Chemotherapy and/or Hematopoietic Stem Cell Transplant
Authors: Prasanth Lingamaneni, Vatsala Katiyar, Krishna Moturi, Binav Baral, Ishaan Vohra, Trilok Shrivastava, Maryam Zia
Journal: Blood (2020)
Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM)
Authors: Claire Jouzier, Amina Cherait, Pascale Cony-Makhoul, Sylvain Thepot, Thomas Cluzeau, Aspasia Stamatoulas Bastard, Pierre Peterlin, Agnes Guerci Bresler, Sophie Dimicoli-Salazar, Gian-Matteo Pica, Stephane Cheze, Clémence Santana, Fatiha Chermat, Pierre Fenaux, Sophie Park
Journal: Blood (2020)
Human Orthogonal IL-2/IL-2Rβ As a Tunable Approach to Enhance CD19-Speific CAR-T Cell Antitumor Activity
Authors: Qian Zhang, Morgan Hresko, Michael Jacob Hollander, Lora Picton, Leon Su, Selene Nunez-Cruz, Jonathan T Sockolosky, K.Christopher Garcia, Michael C. Milone
Journal: Blood (2020)
Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis
Authors: Kazuomi Kario, Satoshi Hoshide, Hiroyuki Mizuno, Tomoyuki Kabutoya, Masafumi Nishizawa, Tetsuro Yoshida, Hideyasu Abe, Tomohiro Katsuya, Yumiko Fujita, Osamu Okazaki, Yuichiro Yano, Naoko Tomitani, Hiroshi Kanegae
Journal: Circulation (2020)

Background: Ambulatory and home blood pressure (BP) monitoring parameters are better predictors of cardiovascular events than are office BP monitoring parameters, but there is a lack of robust data and little information on heart failure (HF) risk. The JAMP study (Japan Ambulatory Blood Pressure Monitoring Prospective) used the same ambulatory BP monitoring device, measurement schedule, and diary-based approach to data processing across all study centers and determined the association between both nocturnal hypertension and nighttime BP dipping patterns and the occurrence of cardiovascular events, including HF, in patients with hypertension. Methods: This practitioner-based, nationwide, multicenter, prospective, observational study included patients with at least 1 cardiovascular risk factor, mostly hypertension, and free of symptomatic cardiovascular disease at baseline. All patients underwent 24-hour ambulatory BP monitoring at baseline. Patients were followed annually to determine the occurrence of primary end point cardiovascular events (atherosclerotic cardiovascular disease and HF). Results: A total of 6,359 patients (68.6±11.7 years of age, 48% men) were included in the final analysis. During a mean±SD follow-up of 4.5±2.4 years, there were 306 cardiovascular events (119 stroke, 99 coronary artery disease, 88 HF). Nighttime systolic BP was significantly associated with the risk of atherosclerotic cardiovascular disease and HF (hazard ratio adjusted for demographic and clinical risk factors per 20-mm Hg increase: 1.21 [95% CI, 1.03–1.41], P =0.017; and 1.36 [95% CI, 1.08–1.71], P =0.009, respectively). Disrupted circadian BP rhythm (riser pattern, nighttime BP higher than daytime BP) was significantly associated with higher overall cardiovascular disease risk (1.48 [95% CI, 1.05–2.08]; P =0.024), and especially HF (2.45 [95% CI, 1.34–4.48]; P =0.004) compared with normal circadian rhythm. Conclusions: Nighttime BP levels and a riser pattern were independently associated with the total cardiovascular event rate, in particular for HF. These findings suggest the importance of antihypertensive strategies targeting nighttime systolic BP. Registration: URL: https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN000020377.
Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
Authors: Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R Shustov, Brian G. Till, Chaitra S. Ujjani, Edward Libby, Mary Philip, Hilary Coye, Christen N. Martino, Sandra Kanan, Karolyn K. Morris, Heather A. Rasmussen, Sanaz Behnia, Margaret E. Nartea, Jenna M. Voutsinas, Ajay K. Gopal
Journal: Blood (2020)
Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma
Authors: Xiran He, Yang Du, Zhijie Wang, Xin Wang, Jianchun Duan, Rui Wan, Jiachen Xu, Pei Zhang, Di Wang, Yanhua Tian, Jiefei Han, Kailun Fei, Hua Bai, Jie Tian, Jie Wang
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background The survival benefits of combining chemotherapy (at the maximum tolerated dose, MTD) with concurrent immunotherapy, collectively referred to as chemoimmunotherapy, for the treatment of squamous cell lung carcinoma (SQCLC) have been confirmed in recent clinical trials. Nevertheless, optimization of chemoimmunotherapy in order to enhance the efficacy of immune checkpoint inhibitors (ICIs) in SQCLC remains to be explored. Methods Cell lines, syngeneic immunocompetent mouse models, and patients’ peripheral blood mononuclear cells were used in order to comprehensively explore how to enhance ectopic lymphoid-like structures (ELSs) and upregulate the therapeutic targets of anti-programmed death 1 (PD-1)/anti-PD-1 ligand (PD-L1) monoclonal antibodies (mAbs), thus rendering SQCLC more sensitive to ICIs. In addition, molecular mechanisms underlying optimization were characterized. Results Low-dose chemotherapy contributed to an enhanced antigen exposure via the phosphatidylinositol 3-kinase/Akt/transcription factor nuclear factor kappa B signaling pathway. Improved antigen uptake and presentation by activated dendritic cells (DCs) was observed, thus invoking specific T cell responses leading to systemic immune responses and immunological memory. In turn, enhanced antitumor ELSs and PD-1/PD-L1 expression was observed in vivo. Moreover, upfront metronomic (low-dose and frequent administration) chemotherapy extended the time window of the immunostimulatory effect and effectively synergized with anti-PD-1/PD-L1 mAbs. A possible mechanism underlying this synergy is the increase of activated type I macrophages, DCs, and cytotoxic CD8 + T cells, as well as the maintenance of intestinal gut microbiota diversity and composition. In contrast, when combining routine MTD chemotherapy with ICIs, the effects appeared to be additive rather than synergistic. Conclusions We first attempted to optimize chemoimmunotherapy for SQCLC by investigating different combinatorial modes. Compared with the MTD chemotherapy used in current clinical practice, upfront metronomic chemotherapy performed better with subsequent anti-PD-1/PD-L1 mAb treatment. This combination approach is worth investigating in other types of tumors, followed by translation into the clinic in the future.
Changes in the Incidence and Overall Survival of Patients with Myeloproliferative Neoplasms between 2002 and 2016 in the United States
Authors: Srdan Verstovsek, Jingbo Yu, Robyn M. Scherber, Shivani Pandya, Christopher Dieyi, Chien-Cheng Chen, Shreekant Parasuraman
Journal: Blood (2020)
Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia
Authors: Paul J. Hampel, Sameer A. Parikh, Timothy G. Call, Mithun Vinod Shah, Nabila Bennani, Aref Al-Kali, Kari G Rabe, Yucai Wang, Eli Muchtar, Jose F. Leis, Saad S. Kenderian, Amber B. Koehler, Susan M. Schwager, Daniel L. Van Dyke, Susan L. Slager, Neil E. Kay, Min Shi, Wei Ding
Journal: Blood (2020)
CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study
Authors: Hind Rafei, Hagop M. Kantarjian, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Joseph D. Khoury, Sa A Wang, Jeffrey L. Jorgensen, Issa F. Khouri, Partow Kebriaei, Nitin Jain, Bouthaina S. Dabaja, Lucia Masarova, Tapan M. Kadia, Shilpa Paul, Dan Nichols, Guillermo Garcia-Manero, Jan A. Burger, Courtney D. DiNardo, Naval Daver, Guillermo Montalban-Bravo, Musa Yilmaz, Prithviraj Bose, Rita Khouri, Philip A. Thompson, Jovitta Jacob, Meagan Rostykus, Rebecca Garris, Marina Konopleva, Susan M. O'Brien, Elias Jabbour
Journal: Blood (2020)
Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Authors: Marissa Locastro, Kah Poh Loh, Andrea M. Baran, Jane L. Liesveld, Michael W. Becker, Kristen Marie O'Dwyer, Eric Huselton, Omar S. Aljitawi, Megan Baumgart, Eric Snyder, Benzi Kluger, Jason H. Mendler
Journal: Blood (2020)
Comparison of Demographics, Treatment Patterns and Outcomes Among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution within the Same Healthcare System
Authors: Akshat M Patel, Omer M Ali, Radhika Kainthla, Syed M Rizvi, Farrukh T Awan, Neil B Desai, Robert Timmerman, Kiran A Kumar, Praveen Ramakrishnan Geethakumari
Journal: Blood (2020)
FIRST EXPERIENCE USING A NON-FENESTRATED CARDIOFORM SEPTAL OCCLUDER FOR CLOSURE OF A GIANT MITRAL PARAVALVULAR LEAK
Authors: Alexandra M. Sanchez, Eduardo Perez, Jose Sleiman, David Lopez, Jose Luis Navia, Nicholas Ghiloni, Hardik M. Bhansali, Nader Hanna, Kevin Leung, Luis Alonso Hernandez Mejia, Diana Miranda Ruiz, Elsy Navas, Roberto J. Cubeddu
Journal: Journal of the American College of Cardiology (2020)
A Pilot/Safety Study of sEphB4-Hsa in Combination with a Hypomethylating Agent for Patients with Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia Previously Treated with a Hypomethylating Agent
Authors: Caitlin O'Neill, Akil Merchant, Parkash S. Gill, Casey L. O'Connell
Journal: Blood (2020)
Assessment of Cerebral Blood Flow and Oxygen Extraction in Pediatric Sickle Cell Disease with Non-Invasive Diffuse Optical Spectroscopies
Authors: Seung Yup Lee, Eashani Sathilingam, Kyle R. Cowdrick, Rowan O. Brothers, Wilbur A. Lam, R. Clark Brown, Clinton H. Joiner, Claudia R. Morris, Erin M. Buckley
Journal: Blood (2020)
IPO11 Regulates the Nuclear Import of BZW1/2 and Is Necessary for AML Cells and Stem Cells
Authors: Boaz Nachmias, Veronique Voisin, Geethu Emily Thomas, Dilshad H. Khan, Rose Hurren, Aaron Botham, Xiaoming Wang, Neil Maclean, Ayesh K Seneviratne, Changjiang Xu, Jonathan St-Germain, Andrea Arruda, Elias Orouji, Liran I. Shlush, Mark D. Minden, Brian Raught, Gary D Bader, Aaron D Schimmer
Journal: Blood (2020)
Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation
Authors: Samer A. Srour, Qaiser Bashir, Denái R. Milton, Yago Nieto, Rohtesh S. Mehta, Neeraj Saini, Ruby Delgado, Gabriela Rondon, Stefan O. Ciurea, Uday R. Popat, Issa F. Khouri, Partow Kebriaei, Elisabet E. Manasanch, Chitra Hosing, Krina K. Patel, Hans C. Lee, Elizabeth J. Shpall, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash
Journal: Blood (2020)